Organogenesis Holdings Inc.
ORGOHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Organogenesis Holdings Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United. With a market capitalization of $127.8M, it sits in micro-cap territory. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chr.
Market Cap
$127.8M
Beta
1.27
P/E (TTM)
—
P/E (Fwd)
-3.20
EPS (TTM)
$-0.83
EPS (Fwd)
$-0.31
ROE
-25.9%
ROA
-4.1%
Cash
$46.1M
Total Debt
$67.0M
Free CF
$28.4M
52W Change
-76.8%
Annual Financials
Cash vs Debt
Where ORGO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ORGO finished 52.11% below its 150-day moving average ($2.13) and 59.52% below its 200-day moving average ($2.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ORGO overbought or oversold?
At the October 20, 2026 close, ORGO's RSI(14) was 18.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Organogenesis Holdings Inc. carries $67.0M in total debt against $46.1M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $28.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -25.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $450.9M (2022) to $563.0M (2025), reflecting a 25% increase over the period.
Investors considering Organogenesis Holdings Inc. should weigh the typical risks associated with ORGO's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing ORGO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.